Alkermes plc.
ALKS · XNASCIK 1520262fmd_18GZ1HWKK2WZ5XT1NYJRKRRAF2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2009 to Sep 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 746 | 903 | 1,094 | 1,171 | 1,039 | 1,174 | 1,112 | 1,663 | 1,558 | 1,476 |
| Cost of revenue | 132 | 155 | 176 | 180 | 178 | 197 | 218 | 253 | 245 | 196 |
| Gross profit | 614 | 749 | 918 | 991 | 860 | 976 | 894 | 1,410 | 1,312 | 1,279 |
| Research and development | 387 | 413 | 425 | 513 | 395 | 291 | 273 | 271 | 245 | 324 |
| Selling, general and administrative | 374 | 422 | 526 | 599 | 539 | 550 | 591 | 690 | 645 | 702 |
| Operating income | (209) | (148) | (99) | (175) | (112) | 98 | (6) | 414 | 421 | 254 |
| Interest expense | 15 | 12 | 15 | 14 | 9 | 11 | 13 | 23 | 23 | 12 |
| Interest and investment income | 4 | 5 | 9 | 14 | 7 | 2 | 8 | 31 | 42 | 45 |
| Other non-operating income (expense) | (6) | 5 | (28) | (22) | 16 | (10) | (25) | 7 | 23 | 37 |
| Income before taxes | (214) | (143) | (127) | (197) | (97) | 88 | (31) | 422 | 444 | 291 |
| Income tax expense | (6) | 15 | 12 | (0) | 14 | 11 | 2 | (98) | 72 | 50 |
| Net income from continuing operations | (208) | (158) | (139) | (197) | (111) | 76 | (33) | 519 | 372 | 242 |
| Net income | (208) | (158) | (139) | (197) | (111) | (48) | (158) | 356 | 367 | 242 |
| Net income to common shareholders | (208) | (158) | (139) | – | – | – | – | – | – | – |